Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 10/2020

01-10-2020 | Melanoma | Research Report

Sex differences in the association between tumor growth and T cell response in a melanoma mouse model

Authors: Panshak P. Dakup, Kenneth I. Porter, Alexander A. Little, Hui Zhang, Shobhan Gaddameedhi

Published in: Cancer Immunology, Immunotherapy | Issue 10/2020

Login to get access

Abstract

Epidemiological evidence suggests that females have an advantage over males in cases of melanoma incidence, progression, and survival. However, the biological mechanisms underlying these sex differences remain unclear. With the knowledge that females generally have a more robust immune system than males, we investigated sex differences in melanoma progression in a B16-F10/BL6 syngeneic mouse model. We observed significantly less tumor volume and growth rate over 14 days in female mice compared to male mice. Furthermore, higher populations of CD4+ and CD8+ T cells, which indicate adaptive immune responses, were found in the circulating blood and tumors of females and corresponded with less tumor growth, and vice versa in males. Our results highlight a mouse model that represents melanoma progression in the human population and displays a higher immune response to melanoma in females compared to males. These findings suggest that the immune system may be one of the mechanisms responsible for sex differences in melanoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Cancer Society Cancer facts & figures 2020. The Society, Atlanta, GA American Cancer Society Cancer facts & figures 2020. The Society, Atlanta, GA
22.
25.
go back to reference Fox HS, Bond BL, Parslow TG (1991) Estrogen regulates the IFN-gamma promoter. J Immunol 146(12):4362–4367PubMed Fox HS, Bond BL, Parslow TG (1991) Estrogen regulates the IFN-gamma promoter. J Immunol 146(12):4362–4367PubMed
28.
go back to reference Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895CrossRefPubMedPubMedCentral Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11(11):3887–3895CrossRefPubMedPubMedCentral
Metadata
Title
Sex differences in the association between tumor growth and T cell response in a melanoma mouse model
Authors
Panshak P. Dakup
Kenneth I. Porter
Alexander A. Little
Hui Zhang
Shobhan Gaddameedhi
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 10/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02643-3

Other articles of this Issue 10/2020

Cancer Immunology, Immunotherapy 10/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine